Drug Profile
Fasedienol - Pherin Pharmaceuticals/VistaGen Therapeutics
Alternative Names: Aloradine IN; Aloradine NS; AM-005; PH-94B; PH94B NSLatest Information Update: 15 Feb 2024
Price :
$50
*
At a glance
- Originator Pherin Pharmaceuticals
- Developer Pherin Pharmaceuticals; VistaGen Therapeutics
- Class Anxiolytics; Behavioural disorder therapies; Small molecules; Steroids
- Mechanism of Action Chemoreceptor cell modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Social phobia
- Phase II Adjustment disorders
Most Recent Events
- 13 Feb 2024 VistaGen Therapeutics plans a phase III PALISADE-3 trial in Social phobia (Intranasal, Spray) in USA in 1H of 2024
- 13 Feb 2024 VistaGen Therapeutics plans a phase III PALISADE-4 trial in Social phobia (In adults) in USA (Intranasal, Spray) in the second half of 2024
- 09 Nov 2023 VistaGen Therapeutics intends to file a New Drug Application (NDA) to the US FDA for Social phobia (In adults) in the first half of 2026